| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000103262284 |
| Molecular Weight (Da) | 427 |
| SMILES | COc1ccc(-n2c(-c3ccc(Cl)cc3)nn(C(=O)NC3CCCCC3)c2=O)cc1 |
| Molecular Formula | C22Cl1N4O3 |
| Action | Antagonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000103262284 |
| Molecular Weight (Da) | 427 |
| SMILES | COc1ccc(-n2c(-c3ccc(Cl)cc3)nn(C(=O)NC3CCCCC3)c2=O)cc1 |
| Molecular Formula | C22Cl1N4O3 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000103262284 |
| Molar Refractivity | 115.77 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| LogP | 6.131 |
| Activity (Ki) in nM | 1513.561 |
| Polar Surface Area (PSA) | 78.15 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000103262284 |
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | - |
| Bsep inhibitor | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.0013163 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.32 |
| Ilogp | 3.9 |
| Xlogp3 | 4.79 |
| Wlogp | 4.25 |
| Mlogp | 3.52 |
| Silicos-it log p | 2.98 |
| Consensus log p | 3.89 |
| Esol log s | -5.53 |
| Esol solubility (mg/ml) | 0.00127 |
| Esol solubility (mol/l) | 0.00000297 |
| Esol class | Moderately |
| Ali log s | -6.16 |
| Ali solubility (mg/ml) | 0.000293 |
| Ali solubility (mol/l) | 0.00000068 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.23 |
| Silicos-it solubility (mg/ml) | 0.00025 |
| Silicos-it solubility (mol/l) | 0.00000058 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.5 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.42 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -6.302 |
| Logd | 4.284 |
| Logp | 5.082 |
| F (20%) | 0.003 |
| F (30%) | 0.011 |
| Mdck | 4.36E-05 |
| Ppb | 0.9582 |
| Vdss | 0.448 |
| Fu | 0.0321 |
| Cyp1a2-inh | 0.307 |
| Cyp1a2-sub | 0.821 |
| Cyp2c19-inh | 0.752 |
| Cyp2c19-sub | 0.535 |
| Cl | 5.414 |
| T12 | 0.314 |
| H-ht | 0.507 |
| Dili | 0.961 |
| Roa | 0.033 |
| Fdamdd | 0.447 |
| Skinsen | 0.248 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.399 |
| Bcf | 0.745 |
| Igc50 | 4.411 |
| Lc50 | 5.134 |
| Lc50dm | 4.791 |
| Nr-ar | 0.075 |
| Nr-ar-lbd | 0.012 |
| Nr-ahr | 0.682 |
| Nr-aromatase | 0.873 |
| Nr-er | 0.919 |
| Nr-er-lbd | 0.034 |
| Nr-ppar-gamma | 0.022 |
| Sr-are | 0.898 |
| Sr-atad5 | 0.898 |
| Sr-hse | 0.019 |
| Sr-mmp | 0.823 |
| Sr-p53 | 0.863 |
| Vol | 416.683 |
| Dense | 1.023 |
| Flex | 0.24 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 2 |
| Qed | 0.676 |
| Synth | 2.344 |
| Fsp3 | 0.318 |
| Mce-18 | 53.103 |
| Natural product-likeness | -1.234 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |